PIK3R5
ENSG00000141506
Target class
Enzyme
Chromosome
17
Approved drugs
0
Clinical candidates (approved and in development)
26
- Approved drugs
- 0
- ClinGen gene-disease validity
- Disputed
- Clinical candidates (approved and in development)
- 26
- Chemical probe available
- No
- Target name
- PIK3R5
- Gene name
- Phosphoinositide-3-kinase regulatory subunit 5
- Gene symbol
- PIK3R5
- Protein name
- Phosphoinositide 3-kinase regulatory subunit 5 (PI3-kinase regulatory subunit 5) (PI3-kinase p101 subunit) (Phosphatidylinositol 4,5-bisphosphate 3-kinase regulatory subunit) (PtdIns-3-kinase regulatory subunit) (Protein FOAP-2) (PtdIns-3-kinase p101) (p101-PI3K)
- P101-PI3K
- p101
- Gene biotype
- Protein coding
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 39
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 59.93
- Tissue specificity (Gini)
- 0.686
- Tissue specificity (tau)
- 0.929
- KEGG gene identifiers
- hsa:23533
- Protein interaction confidence
- 0.899268
- Protein interaction partners
- 41
- R-HSA-114604
- R-HSA-1257604
- R-HSA-1660499
- R-HSA-2219530
- R-HSA-389357
- R-HSA-392451
- R-HSA-6811558
- R-HSA-9027276
- R-HSA-9927354
- End position
- 8965726
- Start position
- 8878911
- Chromosome
- 17
- Strand
- Reverse
- Nucleus . Cytoplasm . Cell membrane
- Peripheral membrane protein . Note=Predominantly localized in the nucleus in absence of PIK3CG/p120. Colocalizes with PIK3CG/p120 in the cytoplasm. Translocated to the plasma membrane in a beta-gamma G protein-dependent manner. .
- Centriolar satellite
- Cytosol
- Tissue specificity (tau)
- 0.92933
- Expression inequality (Gini)
- 0.685606
Expression in transcripts per million
- Whole Blood
- 59.93
- Spleen
- 40.76
- Cells - EBV-transformed lymphocytes
- 34.67
- Lung
- 26.46
- Small Intestine - Terminal Ileum
- 10.37
Expression in transcripts per million
- Whole Blood59.93
- Spleen40.76
- Cells - EBV-transformed lymphocytes34.67
- Lung26.46
- Small Intestine - Terminal Ileum10.37
- Adipose - Subcutaneous7.84
- Adipose - Visceral (Omentum)7.32
- Artery - Coronary6.03
- Testis5.75
- Nerve - Tibial5.51
- Adrenal Gland5.16
- Artery - Aorta4.98
- Bladder4.61
- Fallopian Tube3.98
- Colon - Transverse3.79
- Breast - Mammary Tissue3.59
- Cervix - Endocervix3.08
- Minor Salivary Gland2.76
- Esophagus - Muscularis2.52
- Thyroid2.48
- Colon - Sigmoid2.45
- Esophagus - Gastroesophageal Junction2.43
- Stomach2.42
- Vagina2.36
- Cervix - Ectocervix2.33
And 29 more, listed on the interactive page.
Biological processes
- GO:0007186
- GO:0005829
- GO:0034451
Related records
Trials (197)
- 5G-PEARL: Paxalisib in Malignant Brain Tumours
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
- A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
- A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
- A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
- A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
- A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
- A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Drugs (28)
- Apitolisib PI3-kinase class I inhibitor
- AZD-6482 PI3-kinase class I inhibitor
- BGT-226 PI3-kinase class I inhibitor
- BGT-226 FREE BASE PI3-kinase class I inhibitor
- Buparlisib PI3-kinase class I inhibitor
- Dactolisib PI3-kinase class I inhibitor
- DS-7423 PI3-kinase class I inhibitor
- Gedatolisib PI3-kinase class I inhibitor
- GSK-1059615 PI3-kinase class I inhibitor
- Izorlisib PI3-kinase class I inhibitor
- Omipalisib PI3-kinase class I inhibitor
- Panulisib PI3-kinase class I inhibitor
- Paxalisib PI3-kinase class I inhibitor
- PF-04691502 PI3-kinase class I inhibitor
- Pictilisib PI3-kinase class I inhibitor
- Pilaralisib PI3-kinase class I inhibitor
- Puquitinib PI3-kinase class I inhibitor
- Puquitinib mesylate dihydrate PI3-kinase class I inhibitor
- PWT-33587 PI3-kinase class I inhibitor
- Recilisib PI3-kinase class I inhibitor